New clotting factor combo aims to tame von willebrand bleeding

NCT ID NCT04106908

Ongoing Disease control Sponsor: Octapharma Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at how well Eqwilate, a concentrated mix of two clotting proteins (VWF and FVIII), controls bleeding in people with von Willebrand disease. It includes patients aged 6 and older who use Eqwilate on demand, before surgery, or as regular prevention. Researchers track bleeding control, factor levels, and any side effects in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eqwilate, a concentrate of von Willebrand factor and factor VIII
What this could lead to: If successful, this could confirm Eqwilate as a reliable option for managing bleeding episodes and preventing bleeds during surgery in people with von Willebrand disease.
What could go wrong: This is a small, observational study with no comparison group, so results may not apply to all patients. There is also a risk of developing inhibitors that reduce treatment effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates